evenfolio

Healthcare · NSE: DIVISLAB

Divi's Laboratories

Price as of 12 Nov 2026
11,485.00+1.04%

Q1 FY27 earnings call · Guided by management

Call held 1 Aug 2026 · Read the filing on NSEFiling

₹2,034​CrCapital work in progress · Q1 FY27Divi · p. 7
70​%Share of capex capitalisedDivi · Q&A · p. 13
3,000​litreSPPS unit size · PeptidesDivi · p. 13
85​%UtilisationDivi · Q&A · p. 11
M.Cap
₹3,04,891Cr₹3.05L Cr
P/E
90.7×
1Y return
+76.15%
From 52W high
−2.9%

Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.

Share price

Results Q1 FY27, as filed · consolidated · ₹ Cr

Q1 FY27Q1 FY26YoYQ4 FY26QoQ
Revenue3,0802,410+27.8%2,831+8.8%
EBITDA1,255729+72.2%934+34.4%
EBITDA margin40.8%30.3%+1050 bps33.0%+776 bps
PBTProfit before tax1,180733+61.0%963+22.5%
Net profit902545+65.5%751+20.1%
EPS (₹)33.9520.49+65.7%28.31+19.9%

From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures.

Guidance

Capex70%Three projects about Rs 2,000 crore; about 70% capitalised so far
Capex · FY27Rs 2,034 CrRs 451 crore capitalised in quarter; capital work in progress Rs 2,034 crore

Double-digit growth for the year reiterated

Kiran S. Divi · Whole · Q&A · p. 12
“I would like to stick to my statement saying that we will show double-digit growth no matter what.”

Revenue projection is double-digit growth

Nilima Prasad Divi · Whole · Q&A · p. 13
“We would say, if you want to look at a revenue projection, we are looking at double-digit growth.”

EBITDA margin for the year expected similar to last year

Nilima Prasad Divi · Whole · Q&A · p. 15
“And frankly speaking, if I'm looking at EBITDA margin, it would be the similar as last year.”

More figures from the call

Company · Capacity
80–85​%Utilisation
“But I would say across all the 3 units, it is about 80% to 85% utilization.”
Nilima Prasad Divi · Whole · Q&Ap. 14
Generics · Segments
3–6​monthsTime to commercial volumes for new generics · next 3 to 6 months
“And once the qualification is done, we are expecting in the next 3 to 6 months, only commercial volumes will move out.”
Kiran S. Divi · Whole · Q&Ap. 10
Unit 3 (Kakinada) · Risks
1–2​yearsFDA qualification time · 1 or 2 years
“FDA will take its own time, 1 or 2 years since it’s a new place, and then they will qualify it. In the meantime, we are filling the plant with pre-chemistry products.”
Kiran S. Divi · Whole · Q&Ap. 11

In short

  1. 01Management repeated it expects double-digit growth for the year.
  2. 02Q1 consolidated total income was Rs 3,144 crore against Rs 2,529 crore a year ago; PAT Rs 902 crore against Rs 545 crore.
  3. 03Custom Synthesis was 60% of revenue and Generics 40% in the quarter.
  4. 04The three major capex projects (about Rs 2,000 crore) are nearing completion, with about 70% capitalised; validations are going on.
  5. 05Commercial supply from the validated projects depends on customer and agency qualifications.
  6. 06Raw material stock is now held on a rolling 3-month basis due to West Asia supply risk, at higher cost.
  7. 07Solvent prices rose sharply; the company raised some prices where possible.
  8. 08Peptide capacity is being expanded with several 3,000 litre SPPS units.

Capex

Custom Synthesis: Three major capex programmes nearing completion; validations going on

Kiran S. Divi · Whole · p. 4
“Likewise, the three major capex programmes are nearing completion and validations are going on.”

Capacity

Nutraceuticals: Nutraceutical business expanding capabilities and capacities

Kiran S. Divi · Whole · p. 4
“As we look ahead, we are actively expanding in both capabilities and capacities to meet the demand of a rapidly evolving global market.”

Unit 3 (Kakinada): Long-term plan to get regulatory clearances for Kakinada plant

Kiran S. Divi · Whole · Q&A · p. 11
“But the eventual long-term plan is to qualify Kakinada with all regulatory clearances and start qualifying that plant too.”

Unit 3 (Kakinada): Unit 3 taking a larger role in the production network

Kiran S. Divi · Whole · p. 4
“On the manufacturing front, Unit 3 continues to assume a large role within our production network.”

Unit 3 (Kakinada): Pre-chemistry work moved to Kakinada to free approved plant capacity

Kiran S. Divi · Whole · Q&A · p. 11
“where we need additional capacity and quickly to enhance and utilize existing regulatory approved plant, we are moving a certain amount of chemistry, pre-chemistry works to Kakinada.”

Peptides: Capacity expansion in solid-phase and liquid-phase peptide synthesis

Kiran S. Divi · Whole · p. 4
“Alongside capacity expansion in both solid-phase and liquid-phase peptide synthesis, we continue to strengthen the process development, analytical and manufacturing capabilities required for increasingly complex peptide chemistry.”

Segments

Custom Synthesis: Q1 mix: Custom Synthesis 60% of revenue, Generics 40%

Nilima Prasad Divi · Whole · p. 6
“The business mix for the quarter reflected Custom Synthesis contributing 60% of the revenue and Generics accounting for 40%, respectively.”

Nutraceuticals: Nutraceutical revenue Rs 298 crore vs Rs 250 crore a year ago

Nilima Prasad Divi · Whole · p. 6
“Our global nutraceutical business reported a revenue of ₹298 crores compared with ₹250 crores in the corresponding quarter of last year.”

Generics: Generics volumes stable; pricing reflects competitive conditions

Kiran S. Divi · Whole · p. 3
“Beginning with our Generic business, volumes remained stable during the quarter, while pricing continues to reflect competitive market conditions across products and geographies.”

Custom Synthesis: Validations done; commercial supply after agency qualifications

Kiran S. Divi · Whole · Q&A · p. 8
“All I can say is the validations have been completed, and we would be going commercial as and when the qualifications with the agencies are completed.”

Custom Synthesis: Three major capex projects are for three different products

Kiran S. Divi · Whole · Q&A · p. 17
“So to answer your question, right, if your question is towards the three major projects where the capex is involved, its three different products completely.”

Demand

Generics: Generic price rise reflects raw material costs, not easing price pressure

Kiran S. Divi · Whole · p. 11
“So whatever you're seeing right now is a market correction based on the raw material prices that have taken a substantial hit. It's not based on the markets have corrected and the pricing pressure has gone down.”

Custom Synthesis: Company says it is one of the first CDMOs in India, about 30 years in CDMO

Kiran S. Divi · Whole · Q&A · p. 16
“I mean we are close to, I would say, 30-year-old company who has been in CDMO. We are one of the first CDMOs in India.”

Margins and costs

Gross margin close to 68% this quarter

Nilima Prasad Divi · Whole · Q&A · p. 15
“It's going to be close to 68% this quarter approximately.”

Gross margin was about 60% over the past year

Nilima Prasad Divi · Whole · Q&A · p. 15
“At gross level, I would say it was approximately 60% all over the year.”

Margins slightly higher than previous quarter; quarters are lumpy

Nilima Prasad Divi · Whole · Q&A · p. 9
“We do see the margins slightly higher than the previous quarter. But again, as we always said, there is lumpiness. We always look at year-on-year basis rather than just a quarter.”

Net material consumption 31.2% of standalone revenue

Nilima Prasad Divi · Whole · p. 6
“Net material consumption for the quarter was 31.2% of the revenue from operations on a standalone basis, reflecting the continued benefits of our integrated manufacturing model and product mix.”

Stock is being secured at higher cost to avoid stoppages and delays

Nilima Prasad Divi · Whole · Q&A · p. 10
“And these we are securing at a higher cost to make sure there is no production stoppage and there is no shipments that are delayed to our customers.”

Debt and working capital

Cash Rs 3,611 crore, receivables Rs 3,056 crore, inventory Rs 4,413 crore

Nilima Prasad Divi · Whole · p. 7
“As of the end of the quarter, cash and cash equivalents stood at ₹3,611 crores, trade receivables were ₹3,056 crores and inventory stood at ₹4,413 crores.”

Raw material stocked on rolling 3-month basis to avoid production loss

Nilima Prasad Divi · Whole · p. 10
“we are currently stocking it on a 3 monthly basis. Like any given point of day for the next 3 months, are we secured for our production.”

Validation batch materials also added to inventory

Nilima Prasad Divi · Whole · Q&A · p. 10
“some of our projects, new capex projects have gone into validation batches. And even those materials are being reflected in this. So it's a combination of both that you have seen the increase in the stocks.”

Rolling 3-month stocking decided around March

Nilima Prasad Divi · Whole · Q&A · p. 10
“around March is the time when we decided we would be doing the rolling 3 months, and we would secure the material, and that's why we never had a production loss or a shipment stoppage in the last few months.”

Inventory outlook depends on macro factors outside the company's control

Nilima Prasad Divi · Whole · Q&A · p. 18
“So it all depends on the macroeconomic factors on which we don't have any control on.”

Acquisitions and new business

Generics: About 4 DMFs filed for new generics; validation quantities supplied

Kiran S. Divi · Whole · Q&A · p. 9
“So in the last few years, as we have been validating and then we have filed about 4 DMF so far with various customers. And these are right now, we have supplied validation quantities to them and they're undergoing qualifications as we speak.”

Generics: One generic customer negotiating long-term exclusivity

Kiran S. Divi · Whole · Q&A · p. 10
“One of them actually is trying to look at having exclusivity with us long term. So right now, that negotiation is going on.”

Contrast Media: Long-term iodine contrast media contracts being signed with 2 customers

Kiran S. Divi · Whole · Q&A · p. 15
“So on the Iodine-based contrast media, we are in the process of signing long-term contracts with 2 of the customers. And this will be for multiple years.”

One-offs

Net forex loss of Rs 7 crore vs gain of Rs 39 crore a year ago

Nilima Prasad Divi · Whole · p. 6
“During the quarter, the forex movements resulted in a net forex loss of ₹7 crores compared with a net gain of ₹39 crores in the corresponding quarter of the previous financial year.”

Risks

Solvent supply not easily available every day

Nilima Prasad Divi · Whole · Q&A · p. 14
“I wouldn't say that the supply is easily available every day. I would say this that we were proactive in securing the material 3 months in advance rather than procuring it just in time.”

West Asia situation adds uncertainty to supply chain

Nilima Prasad Divi · Whole · p. 5
“At the same time, the evolving geopolitical situation in West Asia has introduced additional uncertainty into global supply chain.”

Ocean and air freight rates elevated; containers and ISO tanks tight

Nilima Prasad Divi · Whole · p. 6
“Freight rates across both ocean and air transportation remained elevated while the availability of containers and ISO tanks continued to require careful planning and coordination.”

Custom Synthesis: Dedicated projects need regulatory clearances; ready for inspection

Kiran S. Divi · Whole · Q&A · p. 9
“But what I can say is we are completely ready for all regulatory submissions. We are ready for inspection anytime if there is an inspection.”

Contrast Media: Gadolinium project on slow phase, awaiting customer regulatory approval

Kiran S. Divi · Whole · Q&A · p. 16
“the project is on slow phase with them on the Gadolinium side.”

Other

Q1 consolidated total income Rs 3,144 crore vs Rs 2,529 crore

Nilima Prasad Divi · Whole · p. 6
“For the first quarter of FY 2026-27, the Company reported a consolidated total income of ₹3,144 crores compared to ₹2,529 crores in the corresponding quarter of previous financial year.”

Q1 consolidated PAT Rs 902 crore vs Rs 545 crore

Nilima Prasad Divi · Whole · p. 6
“while profit after tax stood at ₹902 crores compared with ₹545 crores in the same period of previous year.”

Q1 consolidated PBT Rs 1,180 crore vs Rs 733 crore

Nilima Prasad Divi · Whole · p. 6
“Profit before tax increased to ₹1,180 crores compared to ₹733 crores in the corresponding quarter of last year”

Standalone PAT Rs 891 crore vs Rs 557 crore

Nilima Prasad Divi · Whole · p. 6
“while profit after tax increased to ₹891 crores from ₹557 crores.”

Standalone revenue grew 10% in constant currency

Nilima Prasad Divi · Whole · p. 6
“On a constant currency basis, the standalone revenue recorded a growth of 10% during the quarter.”

Sources

Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

Search

Search funds, ETFs, stocks, pages and tools